AMENDMENTS TO THE CLAIMS

Claims 1-80 **Canceled**

81. **(Previously Amended)** A GDF-8 analogue which is a GDF-8 polypeptide that has been modified by means of at least two substitutions of a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is selected from more than one of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12, or that has been modified by inserting at least one first amino acid sequence in SEQ ID NO: 11 pr 12 with at least one second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12, 18-30, 42-51, 82-86 and 105-109 in SEQ ID NO: 11 or 12.

82. **(Previously Presented)** An immunogenic composition comprising an immunologically effective amount of a DGF-8 analogue according to claim 81, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.

83. **(Previously Presented)** An immunogenic composition according to claim 82, wherein the adjuvant is selected from the group consisting of an immune targeting adjuvants; an immune modulating adjuvant, such as a toxin a cytokine and a mycobacterial derivative; an oil formulation; a polymer; a micelle forming adjuvant; a saponin; an immunostimulating complex matrix (an ISCOM matrix); a particle; DDA; aluminium adjuvants; DNA adjuvants; γ-insulin; and an encapsulating adjuvant.

84-102 **Canceled**

103. **(Previously Amended)** A GDF-8 analogue which is a GDF-8 polypeptide that has been modified by means of at least two substitutions of a first amino acid sequence in SEQ ID NO: 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is selected from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 12 or that has been modified by inserting at least one first amino acid sequence in SEQ ID NO: 11 or 12 with at least one second amino acid sequence which

comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12,18-30, 42-51, 82-86, and 105-109 in SEQ ID NO:12.

104. **(Previously Presented)** The GDF-8 analogue according to claim 103, wherein the modification is made in residues 18-41 of SEQ ID NO: 12.

105. **(Currently Amended)** A GDF-8 analogue which is a GDF-8 polypeptide that has been modified by at least one modification selected from the group consisting of
- substituting a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign T_H epitope, wherein said first amino acid sequence is from one or more of residues 1-12, 18-41, 43-48, 49-69 or 79-104 in SEQ ID NO: 11 or 12;
- inserting at least one amino acid sequence which comprises a foreign T_H epitope at one or more of residues 1-12, 18-30, 42-51, 82-86 or 105-109 in SEQ ID NO: 11 or 12,
-substituting a first amino acid sequence in SEQ ID NO: 11 or 12 with a second amino acid sequence which comprises a foreign TH epitope, wherein said first amino acid sequence is a loop area or a flexible terminus in the GDF-8 polypeptide comprising SEQ ID NO:11 or 12; and
- inserting at least one amino acid sequence which comprises a foreign T_H epitope into a loop areas or in a flexible terminus in the GDF-8 polypeptide comprising SEQ ID NO: 11 or 12;
wherein the number of amino acid insertions and substitutions does not exceed 60.

106. **(Previously Presented)** The GDF-8 analogue according to claim 105, wherein the foreign T_H epitope is introduced by means of insertion.

107. **Canceled**

108. **(Previously Presented)** The GDF-8 analogue according to claim 105, wherein the foreign T_H epitope is introduced by means of substitution.

109. **(Previously Presented)** The GDF-8 analogue according to claim 105, wherein the foreign T_H epitope is promiscuous.

110. **(Previously Presented)** An immunogenic composition comprising an immunologically effective amount of a GDF-8 analogue according to claim 105, the composition further comprising a pharmaceutically and immunologically acceptable carrier and/or vehicle and optionally an adjuvant.